This is a summary of the European public assessment report (EPAR) for Toviaz. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Toviaz.
Therapeutic Indication
### Therapeutic indication Treatment of the symptoms (increased urinary frequency and / or urgency and / or urgency incontinence) that may occur in patients with overactive-bladder syndrome.
Therapeutic Area (MeSH)
ATC Code
G04BD11
ATC Item
fesoterodine
Pharmacotherapeutic Group
Urologicals
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| fesoterodine fumarate | N/A | 非索罗定 |
EMA Name
Toviaz
Medicine Name
Toviaz
Aliases
N/ANo risk management plan link.
